Compounds targeting pmp22 for the treatment of charcot-marie-tooth disease
US-2024360447-A1 · Oct 31, 2024 · US
US11046727B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11046727-B2 |
| Application number | US-201715682103-A |
| Country | US |
| Kind code | B2 |
| Filing date | Aug 21, 2017 |
| Priority date | Jan 14, 2011 |
| Publication date | Jun 29, 2021 |
| Grant date | Jun 29, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Method and compositions and kits for isolation, identification, and quantification of miRNAs and other small RNAs, including but not limited to, siRNAs, mRNAs, and snRNAs are disclosed. Methods of diagnosing a disease or its progression are also disclosed.
Opening claim text (preview).
The invention claimed is: 1. A method for isolating a multiplicity of miRNA targets from a sample, comprising: a) contacting the sample with a lysis buffer to form a sample lysate; b) contacting the sample lysate with a bead covalently attached to a multiplicity of anti-miRNA probes to form a sample lysate-bead mixture, wherein each of the multiplicity of anti-miRNA probes is configured to selectively hybridize to a different species of the multiplicity of miRNA targets such that each bead comprises a mixture of a multiplicity of different anti-miRNA probe sequences, and wherein each of the multiplicity of anti-miRNA probes is single-stranded and comprises a nucleotide hybridizing portion having complementarity to one of the multiplicity of miRNA targets and a nucleotide linker binding portion for attachment to the bead; c) incubating the sample lysate-bead mixture to form a hybridized complex between at least one of the multiplicity of miRNA targets and at least one of the multiplicity of anti-miRNA probes; d) washing the lysate-bead mixture of step (c) to remove unbound sample lysate material; and e) eluting the hybridized complex to form an elution sample comprising at least one of the multiplicity of miRNA targets. 2. The method according to claim 1 , wherein the bead is a magnetic bead. 3. The method according to claim 2 , wherein the bead is carboxylic acid functionalized bead. 4. The method according to claim 1 , wherein the one or more of the multiplicity of anti-miRNA probes is covalently attached to the bead by ligation of the nucleotide linker binding portion to a bead comprising a DNA molecule (i.e., a DNA bead). 5. The method according to claim 4 , wherein the one or more of the multiplicity of anti-miRNA probes is ligated to the DNA molecule using a single-strand DNA ligase. 6. The method according to claim 1 , wherein the multiplicity of anti-miRNA probes are covalently attached to the bead using a chemical synthesis reaction. 7. The method according to claim 1 , wherein the multiplicity of anti-miRNA probes are covalently attached to the bead using an enzymatic synthesis reaction. 8. The method according to claim 7 , wherein enzymatic synthesis reaction comprises a ligation reaction. 9. The method according to claim 1 , wherein the sample is selected from the group consisting of blood, serum, plasma, urine, saliva, cerebrospinal fluid, wound exudates, biopsies, autopsies, tissues, formalin-fixed, paraffin-embedded (PPFE) samples, and organs. 10. The method according to claim 1 , further comprising a step for: (f) identifying and/or quantifying the multiplicity of miRNA targets. 11. The method according to claim 10 , wherein at least one of the multiplicity of miRNA targets is isolated from the bead before identifying and/or quantifying one or more of the multiplicity of miRNA targets. 12. The method according to claim 10 , wherein the identifying and/or quantifying one or more of the multiplicity of miRNA targets comprises using reverse transcription followed by real-time (RT) or quantitative polymerase chain reaction (q-PCR). 13. The method according to claim 10 , wherein the step for: (f) identifying and/or quantifying is carried out by TaqMan real time PCR. 14. The method of claim 1 , wherein each of the multiplicity of anti-miRNA probes further comprises an additional nucleotides that is not part of the nucleotide hybridizing portion or the nucleotide linker portion. 15. The method according to claim 14 , wherein the additional nucleotide comprises a 3′-dideoxynucleotide. 16. The method of claim 1 , wherein the nucleotide linker binding portion is at the 5′-end of each of the multiplicity of anti-miRNA probes. 17. The method according to claim 16 , wherein the nucleotide linker binding portion comprise a 5′-phosphate group.
by means of a solid support carrier, e.g. particles, polymers · CPC title
Methods for determination or identification of nucleic acids involving differential detection · CPC title
Enzymatic or biochemical coupling of nucleic acids to a solid phase · CPC title
miRNA, siRNA or ncRNA · CPC title
Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.